Bristol-Myers Dodges Revival Of Abilify FCA Suit At 6th Circ.
By Rachel Graf ( October 27, 2017, 4:52 PM EDT) -- A Sixth Circuit panel on Friday declined to revive whistleblowers' False Claims Act suit against pharmaceutical companies Bristol-Myers and Otsuka over alleged kickbacks and off-label promotion for the antipsychotic drug Abilify, saying they haven't proven a link between alleged false statements and claims submitted to the government....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.